

Hundemer Gregory

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8884866/publications.pdf>

Version: 2024-02-01

45
papers

1,485
citations

586496

16
h-index

388640

36
g-index

45
all docs

45
docs citations

45
times ranked

1520
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. <i>Hypertension</i> , 2022, 79, 178-186.	1.3	29
2	Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 681-692.	1.4	10
3	Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. <i>CJC Open</i> , 2022, 4, 315-323.	0.7	8
4	Growing Understanding of the Clinical and Serologic Effects of COVID-19 Vaccines in Patients Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00320122.	2.2	1
5	Urinary Potassium Excretion and Progression From Advanced CKD to Kidney Failure. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210845.	0.6	2
6	Contemporary risk prediction models in chronic kidney disease: when less is more. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 297-302.	1.0	2
7	Independent External Validation and Comparison of Death and Kidney Replacement Therapy Prediction Models in Advanced CKD. <i>Kidney Medicine</i> , 2022, 4, 100440.	1.0	5
8	External Validation of Clinical Prediction Models in Unilateral Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2022, 35, 365-373.	1.0	6
9	Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2022, 35, 561-571.	1.0	7
10	Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism. <i>Frontiers in Endocrinology</i> , 2022, 13, 861581.	1.5	4
11	Performance of the 2021 Race-Free CKD-EPI Creatinine-And Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2022, 80, 462-472.e1.	2.1	13
12	Primary Aldosteronism: State-of-the-Art Review. <i>American Journal of Hypertension</i> , 2022, 35, 967-988.	1.0	26
13	Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis. <i>Hypertension</i> , 2022, 79, 1835-1844.	1.3	20
14	Variability of Aldosterone Measurements During Adrenal Venous Sampling for Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2021, 34, 34-45.	1.0	21
15	Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism. <i>Hypertension</i> , 2021, 77, 891-899.	1.3	49
16	Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110174.	0.6	9
17	Kidney, Cardiac, and Safety Outcomes Associated With β -Blockers in Patients With CKD: A Population-Based Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 178-189.e1.	2.1	21
18	Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 365-373.	2.2	29

#	ARTICLE	IF	CITATIONS
19	How common is primary aldosteronism?. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 353-360.	1.0	14
20	The Case Nephrotic syndrome in a patient with chronic lymphocytic leukemia. <i>Kidney International</i> , 2021, 99, 777-778.	2.6	3
21	Reducing the risk of atrial fibrillation in ESKD: is the devil in the dialysis?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1963-1964.	0.4	0
22	Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2423-2435.	1.8	32
23	Response Letter to the Editor from Zhu et al: "Performance of the Aldosterone-to-Renin Ratio as a Screening Test for Primary Aldosteronism: A Systematic Review and Meta-Analysis" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4300-e4301.	1.8	1
24	Adrenocorticotrophic Hormone-stimulated Adrenal Venous Sampling Underestimates Surgically Curable Primary Aldosteronism: A Retrospective Cohort Study and Review of Contemporary Studies. <i>Hypertension</i> , 2021, 78, 94-103.	1.3	19
25	Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. <i>JAMA Network Open</i> , 2021, 4, e2123365.	2.8	10
26	Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. <i>Pharmacological Research</i> , 2021, 172, 105835.	3.1	19
27	Proteinuria and venous thromboembolism in pregnancy: a population-based cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2101-2107.	1.4	2
28	The Effect of Age on Performance of the Kidney Failure Risk Equation in Advanced CKD. <i>Kidney International Reports</i> , 2021, 6, 2993-3001.	0.4	12
29	β -blockers in hemodialysis: simple questions, complicated answers. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 731-734.	1.4	7
30	Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study). <i>Annals of Intensive Care</i> , 2021, 11, 174.	2.2	3
31	Have We Just Scratched the Surface? A Narrative Review of Uremic Pruritus in 2020. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095402.	0.6	23
32	Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1424-1432.	2.2	23
33	Haemoperfusion should only be used for COVID-19 in the context of randomized trials. <i>Nature Reviews Nephrology</i> , 2020, 16, 697-699.	4.1	10
34	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2020, 36, 596-624.	0.8	324
35	Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. <i>JAMA Internal Medicine</i> , 2020, 180, 1052.	2.6	33
36	MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2020, 183, R185-R196.	1.9	18

#	ARTICLE	IF	CITATIONS
37	Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1241-1255.	0.8	7
38	Is It Time to Recalibrate Cardiac Prediction Tools to Accommodate Chronic Kidney Disease?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1082-1084.	0.8	0
39	Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment. <i>Current Cardiology Reports</i> , 2019, 21, 93.	1.3	17
40	Primary Aldosteronism Diagnosis and Management. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 681-700.	1.2	22
41	Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. <i>Hypertension</i> , 2019, 74, 645-651.	1.3	18
42	Predialysis Care and Cardiovascular Outcomes: Why the Lead Up to Dialysis Matters. <i>Kidney International Reports</i> , 2019, 4, 635-637.	0.4	2
43	Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 51-59.	5.5	417
44	Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. <i>JAMA Cardiology</i> , 2018, 3, 768.	3.0	148
45	Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1835-1843.	1.8	39